“Also, because esophageal cancer is uncommon, even a doubled risk is still a low risk,” she said in a telephone interview.
That is right. This drug people are taking for osteoporosis is DOUBLING the esophageal cancer risk. But kudos both to Jane Green of Oxford University’s Cancer Epidemiology Unit and to Kate Kelland of Reuters for putting it into perspective.
via Common bone drugs linked to esophageal cancer risk | Reuters.